Comparative Analysis and Optimization of Stem Cell Therapies for Type 1 Diabetes: Evaluating Glycemic Control, Insulin Independence, and Adverse Effects

This paper will explore treatments for Type 1 diabetes by comparing embryonic stem cells, adult stem cells, and induced pluripotent stem cells through glycemic control, insulin independence, and other adverse effects. Diabetes is a detrimental disease that affects over 10% of the U.S. population, leading to chronic conditions such as damage to large and small blood vessels, which can increase the risk of a heart attack or stroke, as well as dilemmas with the kidneys, eyes, feet, and nerves. Given the limitations of standard insulin therapy, stem cell transplantation is a promising alternative; however, due to the novelty of the solution, researchers and doctors are not familiar with the most optimal way to treat diabetes. To alleviate and cure this degenerative disease through stem cell transplantation, we will optimize the efficiency of the process by deductively analyzing each stem cell through Continuous Glucose Monitoring (CGM) and monitoring HbA1c levels. We hope to enhance stem cell therapy for type 1 diabetes and save the lives of those suffering from this hoarding pandemic, so victims are effectively cured, not treated. The objective of this study is to find the most suitable stem cell for treating T1D (Type 1 Diabetes) using stem cell transplantation to ensure the safest and most effective route.